Creatd's Flyte Positions for Strategic Expansion Following Verijet Bankruptcy

Stock Information for Bellerophon Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bellerophon Therapeutics Inc.

Flyte, Inc. Expands Vision Jet Fleet to Support 2026 Growth Strategy
Creatd, Inc. Reports Record EPS, Up 75% YoY; Net Equity Surpasses $9 Million
Creatd, Inc. Engages Dawson James Securities, Inc. and Lucosky Brookman, LLP to Execute Uplisting Strategy
Creatd to File Quarterly Financials on Friday, November 14; Schedules Investor Conference Call for Monday, November 17 at 4:30 PM ET
Creatd Launches Flyte Escapes: AI-Enhanced Luxury Travel Experiences for the Modern Era
Creatd, Inc. Approved to Trade on the OTCQB Venture Market with Nearly $10 Million in Positive Net Equity
Creatd, Inc. Files S-1 Registration Statement with SEC, Signaling Readiness for Future National Exchange Uplisting
Creatd, Inc. Swings to $6.4M Positive Net Equity, $32M Turnaround in 18 Months, Sets Stage for Uplist to National Exchange

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.